Last $1.48 USD
Change Today -0.04 / -2.63%
Volume 148.6K
CRIS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 1:30 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Snapshot

Open
$1.52
Previous Close
$1.52
Day High
$1.52
Day Low
$1.46
52 Week High
12/6/13 - $3.65
52 Week Low
10/10/14 - $1.19
Market Cap
127.3M
Average Volume 10 Days
408.9K
EPS TTM
$-0.19
Shares Outstanding
86.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CURIS INC (CRIS)

curis inc (CRIS) Related Businessweek News

No Related Businessweek News Found

curis inc (CRIS) Details

Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

33 Employees
Last Reported Date: 03/13/14
Founded in 2000

curis inc (CRIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $366.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.0K
Vice Chairman and Strategic Advisor
Total Annual Compensation: $464.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $142.8K
Vice President of Technology Management & Int...
Total Annual Compensation: $230.0K
Compensation as of Fiscal Year 2013.

curis inc (CRIS) Key Developments

Curis, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Phase 1 Dose Escalation Data Regarding the Development of Cudc-907

Curis, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $1,764,864 against $7,202,083 a year ago. Loss from operations was $4,753,031 against income from operations of $130,368 a year ago. Net loss was $5,580,143 or $0.06 basic and diluted per share against $1,867,838 or $0.02 basic and diluted per share a year ago. The decrease in Revenue was primarily due to a decrease in license fee revenue, as a result of a $6 million milestone payment earned from Genentech upon the conditional approval of Erivedge by the European Commission in July 2013. For the nine months, the company reported total revenues of $7,850,782 against $13,477,895 a year ago. Loss from operations was $11,051,161 against $4,933,192 a year ago. Net loss was $13,039,864 or $0.15 basic and diluted per share against $8,123,980 or $0.10 basic and diluted per share a year ago. The decrease in Revenue was primarily due to a decrease in license fee revenues from Genentech to $3 million from $10 million for milestone payments earned related to Erivedge in the nine-month periods ending September 30, 2014 and 2013, respectively. The company provided a summary of Phase 1 dose escalation data regarding the development of CUDC-907, Curis' dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, as well as an update on Debio 0932, an oral heat shock protein 90 (HSP90) inhibitor licensed to Debiopharm. A total of 41 patients with relapsed/refractory lymphomas or multiple myeloma have been enrolled thus far, with 10 patients continuing to receive treatment in the dose escalation and expansion phases of the single agent, first-in-human Phase 1 clinical study of CUDC-907. The safety profile of CUDC-907 has been consistent with prior reports of diarrhea and thrombocytopenia as the most frequent adverse events, with diarrhea and hyperglycemia identified as dose limiting toxicities. Using the optimized dose and schedule of administration, adverse events have been manageable and evidence of HDAC and PI3K enzyme modulation has been observed in pharmacodynamic analysis. Among the 8 disease-evaluable patients with diffuse large B-cell lymphoma (DLBCL) treated with CUDC-907 to date, 7 have experienced tumor shrinkage, including 1 patient with a complete response, 2 with partial responses (i.e., tumor shrinkage greater than 50%), and 4 patients with tumor shrinkage ranging from 5% to 46%. Additionally, one subject with multiple myeloma continues to receive CUDC-907 monotherapy treatment for nearly 22 months. Curis recently initiated an expansion cohort to further evaluate CUDC-907 in patients with DLBCL or multiple myeloma at the recommended Phase 2 dose. The company has completed enrollment in all consecutive, escalating dose cohorts at 100, 200 or 300 mg per day in the single-agent Phase 1 study of CUDC-427 in patients with advanced and/or refractory solid tumors or lymphoma. The primary objective of this monotherapy study under the amended protocol is to determine the safety and recommended Phase 2 dose for CUDC-427 when administered orally once daily for two weeks, followed by a one week rest period in 21-day cycles until disease progression or study discontinuation. In addition to safety and tolerability measures, the study protocol includes expansion cohorts intended to enroll patients with specific cancers at the recommended Phase 2 dose.

Curis, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014

Curis, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014 . Venue: Convene (Formerly Sentry Centers), 730 3rd Avenue, New York, New York, United States.

Curis, Inc. to Report Q3, 2014 Results on Nov 10, 2014

Curis, Inc. announced that they will report Q3, 2014 results at 9:00 AM, Eastern Standard Time on Nov 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $1.48 USD -0.04

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.32 USD -0.04
Cytokinetics Inc $4.67 USD +0.08
Delcath Systems Inc $1.24 USD -0.02
MELA Sciences Inc $1.60 USD -0.03
Navidea Biopharmaceuticals Inc $1.24 USD -0.02
View Industry Companies
 

Industry Analysis

CRIS

Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.9x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit www.curis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.